Market Cap: $9.13B
Market Cap: $9.13B

Agree Realty Corporation (Ticker: ADC) announces an increase in its monthly cash dividend, reflecting its commitment to providing steady income for its shareholders. This decision, which raises the di…

Agree Realty (Ticker: ADC) is making headlines with its strategic initiatives aimed at enhancing shareholder value and attracting income-focused investors. The company's recent participation in the Na…
Advancing Oncology Care: Whitehawk Therapeutics Unveils Promising ADC Innovations at AACR Annual Meeting Whitehawk Therapeutics, Inc., a clinical-stage oncology company, prepares for a significant pre…
Piramal Pharma Achieves Milestone in Antibody-Drug Conjugate Manufacturing Piramal Pharma Solutions has attained a significant milestone with the completion of its 1,500th antibody-drug conjugate (ADC…
Analysts Provide Mixed Outlook on Agree Realty as Interest Grows Agree Realty Corporation, a significant player in the retail real estate investment trust (REIT) sector, experiences heightened attenti…
ADC Therapeutics Welcomes New Talent to Enhance Antibody Drug Development ADC Therapeutics SA, a leader in antibody-drug conjugates (ADCs) based in Lausanne, Switzerland, marks a significant milestone…
ADC Therapeutics Restructures Royalty Agreement for Strategic Flexibility ADC Therapeutics SA redefines its financial landscape with a significant amendment to its royalty purchase agreement with Heal…
Strategic Adjustments: ADC Therapeutics' New Royalty Agreement ADC Therapeutics SA, a leader in the development of antibody-drug conjugates, is making significant structural adjustments to enhance its…
Agree Realty and the life‑science real estate ripple from early‑stage biotech activity Main topic — Biotech research momentum reshaping commercial real estate demand Agree Realty is seeing a potential…
Retail REITs eye lab and medical-office demand from oncology commercialization Commercial real estate investors such as Agree Realty are watching early-stage oncology advances for implications on prop…
Biomanufacturing Real Estate: A Niche Opening for Net-lease Owners The recent acceleration of a complex antibody–drug conjugate (ADC) program is sharpening demand for specialized biomanufacturing real…
Agree Realty Reads Biomanufacturing Signal for Real Estate Strategy Agree Realty, a U.S. real estate investment trust known for single-tenant net-lease retail properties, is watching recent contract d…
Mabwell Advances Cancer Treatment with Innovative Antibody-Drug Conjugate Trial Mabwell, an innovation-driven biopharmaceutical company, takes a significant step forward in oncology with the initiatio…
Mabwell Takes a Significant Step in Oncology with U.S. Clinical Trial Launch Mabwell, an innovative biopharmaceutical company, embarks on a pivotal journey in oncology with the initiation of a U.S. cl…
ADC Therapeutics Showcases Commitment to Innovation at Upcoming Healthcare Conference ADC Therapeutics SA, a leader in the field of antibody drug conjugates (ADCs), prepares to present at the 44th Ann…
Unchained Labs Launches ADC Decode to Revolutionize Antibody-Drug Conjugate Research Unchained Labs, a life sciences company headquartered in Pleasanton, California, has unveiled its latest innovation…
Innovative Solutions in Antibody-Drug Conjugate Development: A New Era for Biopharmaceuticals In a significant advancement for the biopharmaceutical sector, Unchained Labs introduces its ADC Decode ap…
Innovative ADC Technologies: A Game Changer for Cancer Treatment Agree Realty, a leader in retail real estate investment, finds itself at the intersection of healthcare advancements and real estate po…
ADC Therapeutics Expands Workforce with Incentive-Based Share Options ADC Therapeutics SA (NYSE: ADCT), a prominent player in the biopharmaceutical sector specializing in antibody drug conjugates (ADC…
### ADC Therapeutics Strengthens Workforce with New Employee Inducement ADC Therapeutics SA, a prominent player in the antibody drug conjugates (ADCs) sector, makes significant strides in workforce de…
Senhwa Biosciences Advances Oncology Research with Promising Drug Combination Senhwa Biosciences, Inc. has recently achieved a significant milestone in its clinical research, announcing the commenceme…
Senhwa Biosciences Advances Cancer Treatment with Pidnarulex in Innovative Trial Senhwa Biosciences, Inc. achieves a significant milestone in oncology research with the initiation of a Phase 1b trial…
Innovent Biologics and Takeda Forge Strategic Alliance to Advance Cancer Therapies Innovent Biologics has successfully finalized a strategic collaboration with Takeda Pharmaceutical Company, aimed at…
Innovent Biologics and Takeda Forge Strategic Collaboration to Advance Cancer Treatments Innovent Biologics announces a significant strategic collaboration with Takeda Pharmaceutical Company aimed at…
OncoPrecision Pioneers Novel Cancer Therapy with ONC001 Presentation at ASH Meeting OncoPrecision Corporation, a cutting-edge translational therapeutics firm, makes significant strides in the fight ag…
Innovative Cancer Therapy ONC001 to Be Presented at ASH Annual Meeting OncoPrecision Corporation announces that its groundbreaking development candidate, ONC001, has been selected for an oral presenta…
Mabwell Advances Cancer Treatment with Innovative Antibody-Drug Conjugate Mabwell, an innovation-driven biopharmaceutical company, recently announces the initiation of its Phase I/II clinical trial fo…
Innovative Collaboration Targets Gastric Cancer Treatment GlycoNex, Inc., a clinical-stage biotechnology firm based in New Taipei City, forges a strategic partnership with Hokkaido University Hospital…
Innovative Collaboration Aims to Enhance Gastric Cancer Treatment Options GlycoNex, Inc., a clinical-stage biotechnology company based in New Taipei City, announces a significant partnership with Hokk…
Pioneering Developments in Biologics Manufacturing: BioDlink's Breakthrough with MEIYOUHENG® In a significant advancement for the biopharmaceutical industry, BioDlink, a leading biologics contract dev…
Innovative Milestone in Biopharmaceuticals: BioDlink and Lepu Biopharma Launch Groundbreaking ADC In a significant advancement for the biopharmaceutical industry, BioDlink, a leading biologics contrac…
BioDlink Achieves Milestone in Biopharma Collaboration with Conditional Approval for Groundbreaking Cancer Treatment BioDlink, a prominent player in biopharmaceutical manufacturing, announces a major…
Breakthrough in Biopharma: BioDlink's Success with EGFR-Targeted ADC BioDlink (1875.HK) achieves a significant milestone in biopharmaceutical innovation by securing conditional marketing approval for…
BioDlink's Groundbreaking Approval Marks a New Era in Biopharma Collaboration BioDlink (1875.HK) achieves a significant milestone by assisting its partner Lepu Biopharma (2157.HK) in receiving conditi…
Mycenax Biotech Partners with RIN Institute to Enhance ADC Capabilities Mycenax Biotech Inc., a leading biologics Contract Development and Manufacturing Organization (CDMO) based in Taiwan, forges a s…
Strategic Innovations at Federal Realty: A Focus on Portfolio Enhancement Federal Realty Investment Trust is currently positioning itself for future growth through a series of strategic initiatives th…
Thousand Oaks Biologics Unveils Advancements in Drug Production at CPHI Frankfurt 2025 Thousand Oaks Biologics, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based i…
ADC Therapeutics Prepares for Investor Engagement with Upcoming Conferences ADC Therapeutics SA, a leader in the development of antibody-drug conjugates (ADCs), is set to increase its visibility and e…
ADC Therapeutics Reinforces Leadership in Antibody Drug Conjugates Through Upcoming Conferences ADC Therapeutics SA, a leader in the antibody-drug conjugate (ADC) sector, is set to participate in a se…
Brixmor Property Group's Strategic Focus on Tenant Relationships and Sustainability Brixmor Property Group, a prominent player in the open-air shopping center sector in the United States, prepares to…
Analysts Weigh In on Agree Realty's Market Position Amid Mixed Sentiments Agree Realty Corporation is currently at the center of attention as six financial analysts provide their insights into the com…
Investor Sentiment Dips Amid Trade Tensions: Implications for Agree Realty In recent days, the investor landscape experiences a noticeable shift as risk sentiment declines significantly. This downturn…
Innovative Cancer Treatments: The Future of GlycoNex's Antibody-Drug Conjugates GlycoNex, Inc., a clinical-stage biotechnology company based in New Taipei City, Taiwan, is making significant strides i…
GlycoNex's Innovative Cancer Treatment Approaches at Upcoming Conference GlycoNex, Inc., a clinical-stage biotechnology company based in New Taipei City, Taiwan, is preparing to present groundbreaking…
Ona Therapeutics Strengthens Leadership with Appointment of Dr. Antoine Yver Ona Therapeutics, a biotech firm focused on developing innovative antibody-drug conjugates (ADCs), announces the appointmen…
Thousand Oaks Biologics Achieves EU GMP Compliance for ADC Manufacturing Thousand Oaks Biologics, a leading player in the biopharmaceutical sector, marks a significant milestone with the successful co…
Sichuan Kelun-Biotech Secures Milestone Approval for Breakthrough Lung Cancer Treatment Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. achieves a significant milestone with the National Medical Pro…
Innovative Breakthrough in Lung Cancer Treatment: Sacituzumab Tirumotecan Approved in China Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. achieves a significant milestone with the approval of its…
Revolutionizing Cancer Therapy Development Through AI Collaboration In a notable advancement for cancer therapy research, Turbine, a pioneer in virtualizing biological experiments with artificial inte…
Innovative Collaborations in Cancer Therapy: Turbine and AstraZeneca's Game-Changing Partnership In an exciting development within the biopharmaceutical industry, Turbine announces a strategic collabo…